Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients with biopsy proven pure chronic allograft injury due to CNI toxicity.~Exclusion Criteria:~1. 24 hour urine protein or spot urine protein/creatinine ratio \> 500 mg/day~2. Estimated glomerular filtration rate (eGFR) \< 30 ml/min by modification of Diet in Renal Disease( MDRD) or 24 hour urine collection~3. Patients with Donor-specific antibody (DSA) by Luminex (mean fluorescence intensity values \> 1,000)~4. Recipients of multiple organ transplants or ABO-incompatible allograft~5. Current panel reactive antibody (PRA) greater than 30 percent~6. Graft loss at randomization~7. Pregnant women~8. Previous history of acute rejection~9. Previous history of allergy or intolerance to Zortress or Myfortic~10. Platelet count less than 100,000~11. White Blood Cell (WBC) less than 3,000~12. Hb less than 9 g/dL or Htc less than 30%~13. Biopsy findings of~    * Chronic antibody mediated rejection~   * Acute rejection~   * Positive C4d staining~   * Interstitial infiltrates more than 25% of the area~   * Transplant glomerulopathy~   * Recurrent or de novo glomerular disease~   * Polyoma nephropathy or positive simian virus 40 (SV40) staining

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Zortress) (Type: EXPERIMENTAL): None
- Reduced dose Tacrolimus (Prograf) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).